Approval · Notice of Compliance 23477 · 2020
NAPROXEN: Notice of Compliance 23477
Issued April 20, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23477
- Date
- April 20, 2020
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling update to comply with the plain language labelling regulations and pm uppdates to algn with canadian reference product
- Canadian reference product
- ALEVE (Bayer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAPROXEN | Not yet assigned | — |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB